These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

474 related items for PubMed ID: 16288028

  • 1. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
    George JA, Chen T, Taylor CC.
    Cancer Res; 2005 Nov 15; 65(22):10381-8. PubMed ID: 16288028
    [Abstract] [Full Text] [Related]

  • 2. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL, Watson JM, Gehrig PA, Fowler WC, Haskill JS.
    Cancer Res; 1999 May 15; 59(10):2425-32. PubMed ID: 10344753
    [Abstract] [Full Text] [Related]

  • 3. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS, Hua J, Gibb RK, Mutch DG, Herzog TJ.
    Gynecol Oncol; 2004 Jul 15; 94(1):67-73. PubMed ID: 15262121
    [Abstract] [Full Text] [Related]

  • 4. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
    Koo JS, Choi WC, Rhee YH, Lee HJ, Lee EO, Ahn KS, Bae HS, Ahn KS, Kang JM, Choi SU, Kim MO, Lu J, Kim SH.
    Life Sci; 2008 Nov 21; 83(21-22):700-8. PubMed ID: 18845169
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells.
    Kim SH, Juhnn YS, Song YS.
    Ann N Y Acad Sci; 2007 Jan 21; 1095():82-9. PubMed ID: 17404021
    [Abstract] [Full Text] [Related]

  • 7. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma.
    Kumar A, Soprano DR, Parekh HK.
    Cancer Res; 2001 Oct 15; 61(20):7552-5. PubMed ID: 11606393
    [Abstract] [Full Text] [Related]

  • 8. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers.
    Goto T, Takano M, Sakamoto M, Kondo A, Hirata J, Kita T, Tsuda H, Tenjin Y, Kikuchi Y.
    Oncol Rep; 2006 May 15; 15(5):1265-71. PubMed ID: 16596196
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents.
    Coley HM, Shotton CF, Ajose-Adeogun A, Modjtahedi H, Thomas H.
    Biochem Pharmacol; 2006 Oct 16; 72(8):941-8. PubMed ID: 16934227
    [Abstract] [Full Text] [Related]

  • 13. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells.
    Kowalski RJ, Giannakakou P, Gunasekera SP, Longley RE, Day BW, Hamel E.
    Mol Pharmacol; 1997 Oct 16; 52(4):613-22. PubMed ID: 9380024
    [Abstract] [Full Text] [Related]

  • 14. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells.
    Li Z, Hu S, Wang J, Cai J, Xiao L, Yu L, Wang Z.
    Gynecol Oncol; 2010 Oct 16; 119(1):125-30. PubMed ID: 20624637
    [Abstract] [Full Text] [Related]

  • 15. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
    Chang CC, Liang YC, Klutz A, Hsu CI, Lin CF, Mold DE, Chou TC, Lee YC, Huang RC.
    Cancer Chemother Pharmacol; 2006 Nov 16; 58(5):640-53. PubMed ID: 16544145
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Potent inhibition of tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole.
    Chu SW, Badar S, Morris DL, Pourgholami MH.
    Anticancer Res; 2009 Oct 16; 29(10):3791-6. PubMed ID: 19846910
    [Abstract] [Full Text] [Related]

  • 18. Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux.
    Chavanpatil MD, Patil Y, Panyam J.
    Int J Pharm; 2006 Aug 31; 320(1-2):150-6. PubMed ID: 16713148
    [Abstract] [Full Text] [Related]

  • 19. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer.
    Duan Z, Foster R, Bell DA, Mahoney J, Wolak K, Vaidya A, Hampel C, Lee H, Seiden MV.
    Clin Cancer Res; 2006 Sep 01; 12(17):5055-63. PubMed ID: 16951221
    [Abstract] [Full Text] [Related]

  • 20. Increased levels of tyrosinated alpha-, beta(III)-, and beta(IV)-tubulin isotypes in paclitaxel-resistant MCF-7 breast cancer cells.
    Banerjee A.
    Biochem Biophys Res Commun; 2002 Apr 26; 293(1):598-601. PubMed ID: 12054644
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.